Literature DB >> 19726797

Translating the cancer genome into clinically useful tools and strategies.

Federico Innocenti, Richard L Schilsky.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19726797     DOI: 10.1242/dmm.004119

Source DB:  PubMed          Journal:  Dis Model Mech        ISSN: 1754-8403            Impact factor:   5.758


× No keyword cloud information.
  6 in total

Review 1.  The use of genomic information to optimize cancer chemotherapy.

Authors:  Federico Innocenti; Nancy J Cox; M Eileen Dolan
Journal:  Semin Oncol       Date:  2011-04       Impact factor: 4.929

2.  Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Authors:  Federico Innocenti; Richard L Schilsky; Jacqueline Ramírez; Linda Janisch; Samir Undevia; Larry K House; Soma Das; Kehua Wu; Michelle Turcich; Robert Marsh; Theodore Karrison; Michael L Maitland; Ravi Salgia; Mark J Ratain
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

Review 3.  Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Authors:  Daniel Crona; Federico Innocenti
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

4.  Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.

Authors:  D J Crona; J Ramirez; W Qiao; A-J de Graan; M J Ratain; R H N van Schaik; R H J Mathijssen; G L Rosner; F Innocenti
Journal:  Pharmacogenomics J       Date:  2015-04-14       Impact factor: 3.550

Review 5.  Systemic therapies for pancreatic cancer--the role of pharmacogenetics.

Authors:  Ross A Soo; Wei-Peng Yong; Federico Innocenti
Journal:  Curr Drug Targets       Date:  2012-06       Impact factor: 3.465

6.  One SNP for both cancer risk and survival in colorectal cancer: two for the price of one?

Authors:  Federico Innocenti
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.